JP2023554097A5 - - Google Patents

Info

Publication number
JP2023554097A5
JP2023554097A5 JP2023537140A JP2023537140A JP2023554097A5 JP 2023554097 A5 JP2023554097 A5 JP 2023554097A5 JP 2023537140 A JP2023537140 A JP 2023537140A JP 2023537140 A JP2023537140 A JP 2023537140A JP 2023554097 A5 JP2023554097 A5 JP 2023554097A5
Authority
JP
Japan
Prior art keywords
seq
bifunctional molecule
molecule according
antigen
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554097A (ja
Filing date
Publication date
Priority claimed from PCT/EP2020/086600 external-priority patent/WO2021122866A1/en
Application filed filed Critical
Priority claimed from PCT/EP2021/086471 external-priority patent/WO2022129512A1/en
Publication of JP2023554097A publication Critical patent/JP2023554097A/ja
Publication of JP2023554097A5 publication Critical patent/JP2023554097A5/ja
Pending legal-status Critical Current

Links

JP2023537140A 2020-12-17 2021-12-17 二機能性抗pd1/il-7分子 Pending JP2023554097A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EPPCT/EP2020/086600 2020-12-17
PCT/EP2020/086600 WO2021122866A1 (en) 2019-12-17 2020-12-17 Bifunctional molecules comprising an il-7 variant
EP21305462 2021-04-09
EP21305462.0 2021-04-09
EP21200350 2021-09-30
EP21200350.3 2021-09-30
PCT/EP2021/086471 WO2022129512A1 (en) 2020-12-17 2021-12-17 Bifunctional anti-pd1/il-7 molecules

Publications (2)

Publication Number Publication Date
JP2023554097A JP2023554097A (ja) 2023-12-26
JP2023554097A5 true JP2023554097A5 (cg-RX-API-DMAC7.html) 2024-12-25

Family

ID=79024880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537140A Pending JP2023554097A (ja) 2020-12-17 2021-12-17 二機能性抗pd1/il-7分子

Country Status (9)

Country Link
US (1) US20240067727A1 (cg-RX-API-DMAC7.html)
EP (1) EP4263606A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023554097A (cg-RX-API-DMAC7.html)
KR (1) KR20230129441A (cg-RX-API-DMAC7.html)
AU (1) AU2021402065A1 (cg-RX-API-DMAC7.html)
CA (1) CA3201729A1 (cg-RX-API-DMAC7.html)
IL (1) IL303745A (cg-RX-API-DMAC7.html)
MX (1) MX2023007301A (cg-RX-API-DMAC7.html)
WO (1) WO2022129512A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022307460A1 (en) * 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
US20240424127A1 (en) * 2023-01-11 2024-12-26 Bright Peak Therapeutics Ag Il-7 polypeptides, immunocytokines comprising same, and uses thereof
CN118359730A (zh) * 2023-01-17 2024-07-19 上海君赛生物科技有限公司 包含细胞因子的靶向型融合蛋白
WO2026052654A1 (en) * 2024-09-03 2026-03-12 F. Hoffmann-La Roche Ag Cytokine receptor agonist

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
KR101163424B1 (ko) * 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Il-7 융합 단백질
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Il−2媒介性免疫応答の有効性を高める組成物および方法
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
JP7102670B2 (ja) * 2018-01-25 2022-07-20 アイ-エムエービー バイオファーマ ユーエス リミテッド 抗pd‐l1抗体とil‐7との融合
KR20210003814A (ko) * 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
CA3097593A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
US11491838B2 (en) 2018-07-10 2022-11-08 Iveco S.P.A. Suspension for a vehicle
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
AU2019406452B2 (en) 2018-12-21 2021-09-16 Ose Immunotherapeutics Humanized anti-human-PD-1 antibody
CN110256583B (zh) * 2019-07-11 2022-05-20 中国科学院生物物理研究所 一种il-2突变体与抗体的融合蛋白及其应用
TW202136287A (zh) * 2019-12-17 2021-10-01 法商Ose免疫治療公司 包含il-7變體之雙官能分子

Similar Documents

Publication Publication Date Title
JP2019533441A5 (cg-RX-API-DMAC7.html)
FI3177643T5 (fi) T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä
JP2019530434A5 (cg-RX-API-DMAC7.html)
JP2018516537A5 (cg-RX-API-DMAC7.html)
JP2024119791A5 (cg-RX-API-DMAC7.html)
JP2019501883A5 (cg-RX-API-DMAC7.html)
RU2019141289A (ru) АНТИ-SIRPα АНТИТЕЛА
US20210198368A1 (en) Multispecific molecules targeting cll-1
JP2019500892A5 (cg-RX-API-DMAC7.html)
JP7853916B2 (ja) 免疫複合体
JP2021521275A5 (cg-RX-API-DMAC7.html)
WO2020023702A1 (en) Novel il-21 prodrugs and methods of use thereof
JP2022512649A5 (cg-RX-API-DMAC7.html)
JP2020502233A5 (cg-RX-API-DMAC7.html)
JP2021525082A5 (cg-RX-API-DMAC7.html)
RU2016133347A (ru) Варианты fc-области с улучшенной способностью связываться с белком а
RU2018143439A (ru) Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf и pd1-связывающий фрагмент
JP2017504566A5 (cg-RX-API-DMAC7.html)
JP2019500893A5 (cg-RX-API-DMAC7.html)
JP2019502712A5 (cg-RX-API-DMAC7.html)
RU2019108429A (ru) Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
JP2018525382A5 (cg-RX-API-DMAC7.html)
CA3086653A1 (en) Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa)
JP2018520650A5 (cg-RX-API-DMAC7.html)
JP2012530496A5 (cg-RX-API-DMAC7.html)